Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Akhil Kapur
Presenter report:Kapur, Akhil (United Kingdom)WebcastThe CARDia trial (Coronary Artery Revascularisation in Diabetes – 510 patients) is the largest randomised trial specifically comparing coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) in patients with diabetes and multivessel disease to date. The BARI trial (which recruited patients from 1987 to 1991) had a subset of 353 diabetic patients and suggested that CABG patients had improved survival compared to angioplasty, a finding which has guided practice since then.Preliminary results of the CARDia trial at one year show no apparent difference between CABG and PCI in terms of the composite endpoints of death, non fatal MI and non fatal stroke (10.2% vs. 11.6%, p=0.63). Comparison of the individual endpoints of CABG vs. PCI were as follows: death (3.3% vs. 3.2%, p=0.83), non fatal MI (5.7% vs. 8.4%, p= 0.25) and non fatal stroke (2.5% vs. 0.4%, p=0.09). Repeat revascularisation was higher in the PCI group as expected with a rate of 9.9% vs. 2.0% for CABG. Comparing CABG and a subgroup of 179 PCI patients who received drug eluting Cypher stents rather than bare metal stents, the composite endpoint of death, non fatal MI and non fatal stroke was 10.2% vs. 10.1% (p=0.98) again showing no difference in this composite endpoint.CARDia shows that at 1 year, there is no apparent difference between CABG and PCI in terms of death or the composite of death, non fatal MI and non fatal stroke and suggests that PCI is a safe alternative to CABG in selected patients with diabetes and multi-vessel coronary artery disease. “We are very excited about these results. For the first time we have evidence from a randomised trial using modern treatments that PCI may offer safe coronary revascularisation in diabetic patients compared to surgery.” said Akhil Kapur, Study Director and presenter at the hotline clinical trials session at the ESC Congress in Munich on September 1st 2008.
Discussant: Fuster Valentin (United States of America)
Hot Line Update II
This congress report accompanies a presentation given at the ESC Congress 2008. Written by the author himself/herself, this report does not necessarily reflect the opinion of the European Society of Cardiology.